CA Patent

CA2069162A1 — Use of nizatidine to treat reflux esophagitis

Assigned to Eli Lilly and Co · Expires 1992-11-29 · 33y expired

What this patent protects

Abstract of the Invention The present invention provides a method for treating reflux esophagitis in a mammal suffering from same which comprises administering to said mammal nizatidine in dosage amounts typically associated with conventional ulcer dosage regimens. The instantly…

USPTO Abstract

Abstract of the Invention The present invention provides a method for treating reflux esophagitis in a mammal suffering from same which comprises administering to said mammal nizatidine in dosage amounts typically associated with conventional ulcer dosage regimens. The instantly claimed method not only provides a method for relieving the major symptoms associated with reflux esophagitis, such as heartburn, but also provides for healing of moderate-to-severe reflux esophagitis.

Drugs covered by this patent

Patent Metadata

Patent number
CA2069162A1
Jurisdiction
CA
Classification
—
Expires
1992-11-29
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.